Alnylam Pharmaceuticals said this week that it is investigating the use of RNAi to treat and prevent highly pathogenic influenza.

The project, however, is not an effort the company categorizes as a formal development program at this point. Currently, Alnylam considers only its age-related macular degeneration and respiratory syncytial virus projects as likely to enter human testing in the near term. The company has said, however, that it plans to announce the third main development program before the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.